amifostine anhydrous has been researched along with vidarabine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cortes, JE; Giles, FJ; Kantarjian, HM; Keating, AR; Keating, MJ; O'Brien, SM; Shi, GG; Thomas, D | 1 |
| Li, SX; Liu, Y; Lu, XC; Zhu, HL | 1 |
1 trial(s) available for amifostine anhydrous and vidarabine
| Article | Year |
|---|---|
Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Radiation-Protective Agents; Sepsis; Survival Rate; Vidarabine | 2003 |
1 other study(ies) available for amifostine anhydrous and vidarabine
| Article | Year |
|---|---|
[Curative efficacy of fludarabine combined with rituximab and amifostine on aged patient with B-chronic lymphocytic leukemia].
Topics: Aged; Amifostine; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Rituximab; Treatment Outcome; Vidarabine | 2007 |